Novartis, USFDA agree to malaria drug trial: COVID-19

Whether hydroxychloroquine will be beneficial for patients with COVID-19 disease

456
Laboratory test chemical
Picture: Pixabay

ZURICH: Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-19 disease in 440 hospitalised patients, the Swiss drugmaker said.

The decades-old medicine has received U.S. Food and Drug Administration (FDA) emergency use authorization for coronavirus disease, but so far there is no scientific proof it helps those afflicted.

Also read: HCQ could have side-effects: ICMR

“We recognize the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with COVID-19 disease,” said John Tsai, Novartis’s top drug developer.

The drug, also used to treat lupus and rheumatoid arthritis, has been promoted by President Donald Trump, with some worried the administration’s advocacy for an unproven medicine for COVID-19 has short-circuited the oversight process.